New therapeutic targets in stroke prevention: the effects of allopurinol on the cerebrovasculature of patients with subcortical stroke

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN06452574

Enrollment

Registered

2005-11-22

Start date

2005-11-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subcortical stroke. Circulatory System Stroke

Interventions

3 month allopurinol treatment (300 mg) versus lactose tablet.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subcortical stroke 2. Index stroke within 2 weeks and 3 months prior to randomisation

Exclusion criteria

Exclusion criteria: 1. >70% Internal carotid artery stenosis 2. Coronary artery disease 3. Other significant comorbidity 4. Contraindication to allopurinol 5. Contraindication to acetazolamide 6. Concurrent azathioprine or 6-mercaptopurine therapy 7. Serum creatinine >250 µmol/l 8. Woman of childbearing potential

Design outcomes

Primary

Measure	Time frame
The change in flow velocity in the middle cerebral artery (MCA) following acetazolomide infusion.	—

Secondary

Measure	Time frame
1. Change in serum urate 2. Recurrent stroke or other cardiac event	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026